NEUROCRINE
Live / Applied — Third extension granted (statement of use) (as of 26 Feb 2026)
What this means for you
Not registered yet, but its 21 Sept 2023 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 98191100
- Mark type
- Stylized text
- Filed
- 21 Sept 2023
- Published for opposition
- 18 Jun 2024
- Attorney of record
- Allison Strickland Ricketts
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical preparations for human use for the treatment of endocrine, hormonal, and genetic diseases, disorders, and conditions; Pharmaceutical preparations for human use for the prevention and treatment of diseases, disorders, and conditions by gene therapy; Pharmaceutical preparations for human use for the prevention and treatment of diseases, disorders, and conditions by gene therapy, namely, Friedreich's ataxia, Parkinson's disease, GBA1-mediated diseases, and congenital birth defects; Pharmaceutical preparations for human use for the treatment of rare and orphan diseases, disorders, and conditions, namely, rare pediatric epilepsies, SCN8A developmental and epileptic encephalopathy, and congenital adrenal hyperplasia; Pharmaceutical preparations for human use for the treatment of schizophrenia, adjunctive treatment of schizophrenia, cognitive impairment associated with schizophrenia, epilepsy, epileptic encephalopathy with continuous spike-and-wave during sleep, SCN8A-related epilepsy with encephalopathy, focal onset seizures, Parkinson's Disease, adjunctive treatment of Parkinson's Disease, Major Depressive Disorder, anhedonia in Major Depressive Disorder, inadequate response to treatment in Major Depressive Disorder, dyskinetic cerebral palsy, and neuro-immunological and neuroendocrinological diseases, disorders, and conditions
- Class 044 — Medical, beauty and agricultural services: Providing medical information in the field of gene therapy
Owner
- Neurocrine Biosciences, Inc., San Diego, CA, US
- Neurocrine Biosciences, Inc., San Diego, CA, US
Prosecution history
- 26 Feb 2026 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 26 Feb 2026 — SOU EXTENSION 3 GRANTED
- 12 Feb 2026 — SOU EXTENSION 3 FILED
- 12 Feb 2026 — SOU TEAS EXTENSION RECEIVED
- 12 Aug 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 11 Aug 2025 — SOU EXTENSION 2 GRANTED
- 04 Aug 2025 — SOU EXTENSION 2 FILED
- 05 Aug 2025 — SOU TEAS EXTENSION RECEIVED
- 20 Mar 2025 — TEAS CHANGE OF CORRESPONDENCE RECEIVED
- 20 Mar 2025 — APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
- 20 Mar 2025 — TEAS CHANGE OF OWNER ADDRESS RECEIVED
- 17 Jan 2025 — DIVISIONAL PROCESSING COMPLETE
- 24 Sept 2024 — DIVISIONAL REQUEST RECEIVED
- 20 Dec 2024 — RESPONSE TO ITU OFFICE ACTION ENTERED
- 20 Dec 2024 — TEAS RESPONSE TO OFFICE ACTION RECEIVED